Improving processes for blood factor products: From blood bank to hospital pharmacy

Summa, Maria A.; Culligan, Michael W.; Nabors, Patricia

doi:10.2146/ajhp080708

Cited by 3 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many of these newer blood component products are approved by FDA as medications and, as such, should be overseen by the P&T committee as well. Examples of this include erythropoiesis‐stimulating agents, newer topical hemostatic agents, and coagulation factors …”

Section: Select Products With Possible Oversight From the Blood Bankmentioning

confidence: 99%

“…The American Hospital Formulary System (AHFS) is the recognized formulary structure of choice for medication classification in the United States. This recognition includes not only national organizations, but also federal recognition, The AHFS classifies medications with similar pharmacologic, therapeutic, and/or chemical characteristics and is published on an annual basis . Many of these products are stored in the laboratory or blood bank in some institutions.…”

Section: Select Products With Possible Oversight From the Blood Bankmentioning

confidence: 99%

“…Examples of this include erythropoiesis-stimulating agents, newer topical hemostatic agents, and coagulation factors. 8,9 The American Hospital Formulary System (AHFS) is the recognized formulary structure of choice for medication classification in the United States. This recognition includes not only national organizations, but also federal recognition, 8,10 The AHFS classifies medications with similar pharmacologic, therapeutic, and/or chemical characteristics and is published on an annual basis.…”

mentioning

confidence: 99%

“…This recognition includes not only national organizations, but also federal recognition, 8,10 The AHFS classifies medications with similar pharmacologic, therapeutic, and/or chemical characteristics and is published on an annual basis. 8,10 Many of these products are stored in the laboratory or blood bank in some institutions. Table 1 lists selected blood derivative products.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Applying principles of formulary management to blood banking

et al. 2012

View full text Add to dashboard Cite

The pharmacy and therapeutics (P&T) committee or its equivalent has been a long-standing committee of the medical staff in almost every institution. The P&T committee is typically defined as the body that recommends policy to the medical staff and the administration of the organization on matters related to the safe and therapeutic use of medications as well as other matters relating to medication use. The Food and Drug Administration definition of a drug includes blood and blood components, and the American Society of Health-System Pharmacists guidelines suggest including blood derivatives in their definition of a drug. Clinicians and other health care providers have needed to become more familiar with blood and blood component therapy as more prescription blood products have become available. As such, the P&T committee could work collaboratively with blood bank personnel, who are experts in this area, to help ensure that blood derivative products undergo the same evidence-based formulary review process as other medications.

show abstract

Section: Select Products With Possible Oversight From the Blood Bankmentioning

confidence: 99%

Section: Select Products With Possible Oversight From the Blood Bankmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations